2024-01-182024-01-182021-12Ardıçlı, Ö. (2021). "Advances and highlights in biomarkers of allergic diseases". Allergy: European Journal of Allergy and Clinical Immunology, 76(12), 3659-3686.0105-45381398-9995https://onlinelibrary.wiley.com/doi/10.1111/all.15089https://hdl.handle.net/11452/39132Çalışmada 28 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.During the past years, there has been a global outbreak of allergic diseases, presenting a considerable medical and socioeconomical burden. A large fraction of allergic diseases is characterized by a type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, eosinophils, mast cells, and M2 macrophages. Biomarkers are valuable parameters for precision medicine as they provide information on the disease endotypes, clusters, precision diagnoses, identification of therapeutic targets, and monitoring of treatment efficacies. The availability of powerful omics technologies, together with integrated data analysis and network-based approaches can help the identification of clinically useful biomarkers. These biomarkers need to be accurately quantified using robust and reproducible methods, such as reliable and point-of-care systems. Ideally, samples should be collected using quick, cost-efficient and noninvasive methods. In recent years, a plethora of research has been directed toward finding novel biomarkers of allergic diseases. Promising biomarkers of type 2 allergic diseases include sputum eosinophils, serum periostin and exhaled nitric oxide. Several other biomarkers, such as pro-inflammatory mediators, miRNAs, eicosanoid molecules, epithelial barrier integrity, and microbiota changes are useful for diagnosis and monitoring of allergic diseases and can be quantified in serum, body fluids and exhaled air. Herein, we review recent studies on biomarkers for the diagnosis and treatment of asthma, chronic urticaria, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, food allergies, anaphylaxis, drug hypersensitivity and allergen immunotherapy. In addition, we discuss COVID-19 and allergic diseases within the perspective of biomarkers and recommendations on the management of allergic and asthmatic patients during the COVID-19 pandemic.eninfo:eu-repo/semantics/closedAccessAllergen immunotherapyallergic diseasesbiomarkersCOVID-19precision medicineSublingual immunotherapyPrecısıon medıcıneAsthmaMechanısmsEndotypesCellsImmunologyPhenotypesInductionToleranceBiomarkersCOVID-19HumansHypersensitivityImmunity, innateLymphocytesPandemicsRhinitis, allergicSARS-CoV-2Article0007001102000012-s2.0-8511568997436593686761234519063https://doi.org/10.1111/all.15089AllergyImmunologySublingual Immunotherapy; Desensitization; AllergoidBenralizumabBiological markerDupilumabIcosanoidMepolizumabMicroRNANitric oxideOmalizumabReslizumabAllergic diseaseAllergic rhinitisAnaphylaxisAsthmaAtopic dermatitisChronic rhinosinusitisChronic urticariaCoronavirus disease 2019Data analysisDrug hypersensitivityExpired airFood allergyHumanImmune responseM2 macrophageMast cellMicrofloraNon invasive procedurePandemicPersonalized medicineQuantitative analysisReviewSputumTh2 cell;Allergic rhinitisHypersensitivityInnate immunityLymphocyte